Compare IQIYI Inc - ADR (IQ) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Sana Biotechnology Inc — how do they compare? IQIYI Inc - ADR trades at $1.02 (market cap $974.67M), while Sana Biotechnology Inc trades at $2.84 (market cap $836.71M). The key difference: IQIYI Inc - ADR is the larger of the two by market cap, and IQIYI Inc - ADR is more actively traded (4,964,108 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Sana Biotechnology Inc for 23 Days on average.
| IQ | SANA | |
|---|---|---|
Market Cap | $974.67M | $836.71M |
Volume | 4,964,108 | 4,507,444 |
Sector | Media | Health |
52-Week High | $2.35 | $5.92 |
52-Week Low | $0.86 | $2.68 |
Typical Hold Time | 55 Days | 23 Days |
Enterprise Value | $2.47B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQ trades at $1.025, up 0.99% today, but technicals are bearish with mixed sentiment. The company reported a net loss of $206.31M in 2025 despite beating EPS estimates in recent quarters. Revenue declined to $27.29B, and profitability metrics like ROE are negative. Analyst consensus is split with 50% buy ratings, but cash flow trends show volatility, and the firm is heavily investing in AI-driven content.
Outlook is cautious; while AI initiatives offer growth potential, core streaming pressures and persistent losses pose risks. The stock's low P/S and P/B suggest undervaluation, but investor confidence hinges on a return to profitability and successful execution of new content strategies amid competitive and macroeconomic challenges.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
